NCT05688280View on ClinicalTrials.gov

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Metastatic Solid TumorColon CancerNonsmall Cell Lung CancerSoft Tissue Sarcoma
Interventions
DRUG

1.0% IP-001 for Injection

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Trial Locations (16)

6500

IOSI Ospedale San Giovanni Bellinzona, Bellinzona

7000

Kantonsspital Graubunden, Chur

33076

Institut Bergonie, Bordeaux

33146

Miami Cardiac & Vascular Institute, Coral Gables

40202

University of Louisville Physicians, PSC, Louisville

60590

Johann Wolfgang Goethe-Univresitat Frankfurt/Main, Frankfurt

73104

Stephenson Cancer Center, Oklahoma City

74078

SLK-Kliniken Heilbronn GmbH, Heilbronn

75013

Hospitalier Pitie-Salpetriere, Paris

81925

Munchen Klinik Bogenhausen, Munich

92150

Hôpital Foch, Suresnes

94805

Institut Gustave Roussy, Villejuif

CH-3010

Inselspital Universitatsspital, Bern, Bern

CH-9007

Kantonsspital St. Gallen, Sankt Gallen

W1T 7HA

University College London Hospitals, London

OX3 7LJ

Churchill Hospital, Oxford

Sponsors
All Listed Sponsors
lead

Immunophotonics, Inc.

INDUSTRY

NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS | Biotech Hunter | Biotech Hunter